Prinolid 3,75 3,75 mg Injection
PDF Leaflet Revision Date: 24 January 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Management of endometriosis, prostate cancer, breast cancer, and central precocious puberty.
Dosage (summary)
3.75 mg subcutaneously once a month for adults; individualized for children based on weight.
Special Populations
- Hepatic impairment
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- QT prolonging agents
- Anti-androgens
Contraindications
- Hypersensitivity to leuprolide
- Pregnancy
- Breastfeeding
- Undiagnosed vaginal bleeding
Common side effects
- Hot flushes
- Mood swings
- Vaginal dryness
- Headache
- Nausea
Counselling Points
- Use non-hormonal contraception
- Report any unusual bleeding
- Monitor for signs of depression
Serious warnings
- Risk of diabetes
- Potential for cardiovascular events
- Bone density loss
Important Disclaimer
The Prinolid 3,75 3,75 mg Injection professional information leaflet below is the property of Eurolab and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
